Tempus AI, Inc. (TEM)
NASDAQ: TEM · Real-Time Price · USD
62.69
+1.32 (2.15%)
At close: May 12, 2025, 4:00 PM
63.36
+0.67 (1.07%)
After-hours: May 12, 2025, 7:59 PM EDT
Tempus AI Revenue
Tempus AI had revenue of $255.74M in the quarter ending March 31, 2025, with 75.38% growth. This brings the company's revenue in the last twelve months to $803.32M, up 42.93% year-over-year. In the year 2024, Tempus AI had annual revenue of $693.40M with 30.38% growth.
Revenue (ttm)
$803.32M
Revenue Growth
+42.93%
P/S Ratio
11.44
Revenue / Employee
$334,715
Employees
2,400
Market Cap
10.85B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
TEM News
- 5 days ago - Tempus AI Rallies After Q1 Beat, Analyst Notes AI-Driven Platform And Expanding Pharma Deals - Benzinga
- 6 days ago - Tempus AI, Inc. (TEM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Tempus Reports First Quarter 2025 Results - Business Wire
- 7 days ago - Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry - Business Wire
- 11 days ago - Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment - Business Wire
- 13 days ago - Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection - Business Wire
- 14 days ago - Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform - Business Wire
- 17 days ago - Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - Business Wire